LeMaitre Vascular (LMAT) revenue and earnings history
LeMaitre Vascular reported revenue of $250M for fiscal 2025 (year ended Dec 31, 2025), +13.5% on the year before, and net income of $57.7M.
Over 16 years, from fiscal 2009 to fiscal 2025, revenue grew at a compound rate of +10.4% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $250M+13.5% | $67.9M | $57.7M | $81.3M | $6.78M | $74.5M | $7.83M | $1.82M | $18.1M | $28.2M | — | 10-K |
| 2024 |
The latest quarter, insider trades and fund moves: LeMaitre Vascular (LMAT) on OQRO.
Common questions
What was LeMaitre Vascular's revenue in fiscal 2025?
$250M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 26, 2026. That is +13.5% on fiscal 2024 ($220M).
How fast has LeMaitre Vascular's revenue grown?
From $50.9M in fiscal 2009 to $250M in fiscal 2025: a compound annual growth rate of +10.4% over 16 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure LeMaitre Vascular tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
